Discovery of novel 2-(4-(benzyloxy)-5-(hydroxyl) phenyl) benzothiazole derivatives as multifunctional MAO-B inhibitors for the treatment of Parkinson’s disease

References

• Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021; 397(10291):2284–2303.
   PubMed Web of Science ®Google Scholar
• Hayes MT. Parkinson’s disease and Parkinsonism. Am J Med. 2019;132(7):802–807.
   PubMed Web of Science ®Google Scholar
• Dorsey ER, Elbaz A, Nichols E, Abbasi N, Abd-Allah F, Abdelalim A, Adsuar JC, Ansha MG, Brayne C, Choi J-YJ, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):939–953.
   PubMed Web of Science ®Google Scholar
• Azam F, El-Gnidi BA, Alkskas IA, Ahmed MA. Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice. J Enzyme Inhib Med Chem. 2010;25(6):818–826.
   PubMed Web of Science ®Google Scholar
• Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson’s disease: implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020;134:104700.
   PubMed Web of Science ®Google Scholar
• Tan YY, Jenner P, Chen SD. Monoamine oxidase-B inhibitors for the treatment of Parkinson’s disease: past, present, and future. J Parkinsons Dis. 2022;12(2):477–493.
   PubMedGoogle Scholar
• Group PMC. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196–1205.
   PubMed Web of Science ®Google Scholar
• Santin Y, Resta J, Parini A, Mialet-Perez J. Monoamine oxidases in age-associated diseases: new perspectives for old enzymes. Ageing Res Rev. 2021;66:101256.
   PubMed Web of Science ®Google Scholar
• Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, Ahmad S, Silva Correia IF, Chandra A, Nansubuga EP, et al. Targeting oxidative stress mechanisms to treat Alzheimer’s and Parkinson’s disease: a critical review. Oxid Med Cell Longev. 2022;2022:7934442.
   PubMed Web of Science ®Google Scholar
• Raj K, Kaur P, Gupta GD, Singh S. Metals associated neurodegeneration in Parkinson’s disease: insight to physiological, pathological mechanisms and management. Neurosci Lett. 2021;753:135873.
   PubMed Web of Science ®Google Scholar
• Knorle R. Neuromelanin in Parkinson’s disease: from Fenton reaction to calcium signaling. Neurotox Res. 2018;33(2):515–522.
   PubMed Web of Science ®Google Scholar
• Thapa K, Khan H, Kanojia N, Singh TG, Kaur A, Kaur G. Therapeutic insights on ferroptosis in Parkinson’s disease. Eur J Pharmacol. 2022;930:175133.
   PubMed Web of Science ®Google Scholar
• Bisaglia M, Bubacco L. Copper ions and Parkinson’s disease: why is homeostasis so relevant? Biomolecules. 2020;10(2):195.
   PubMed Web of Science ®Google Scholar
• Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–673.
   PubMed Web of Science ®Google Scholar
• Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157–172.
   PubMed Web of Science ®Google Scholar
• Sarkar S, Nguyen HM, Malovic E, Luo J, Langley M, Palanisamy BN, Singh N, Manne S, Neal M, Gabrielle M, et al. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson’s disease. J Clin Invest. 2020;130(8):4195–4212.
   PubMed Web of Science ®Google Scholar
• Liu TW, Chen CM, Chang KH. Biomarker of neuroinflammation in Parkinson’s disease. Int J Mol Sci. 2022;23(8):4148.
   PubMed Web of Science ®Google Scholar
• Sasaki NA, Sonnet P. A novel multi-target strategy to attenuate the progression of Parkinson’s disease by diamine hybrid AGE/ALE inhibitor. Future Med Chem. 2021;13(24):2185–2200.
   PubMed Web of Science ®Google Scholar
• Carradori S, Ortuso F, Petzer A, Bagetta D, De Monte C, Secci D, De Vita D, Guglielmi P, Zengin G, Aktumsek A, et al. Design, synthesis and biochemical evaluation of novel multi-target inhibitors as potential anti-Parkinson agents. Eur J Med Chem. 2018;143:1543–1552.
   PubMed Web of Science ®Google Scholar
• Anastassova N, Aluani D, Hristova-Avakumova N, Tzankova V, Kondeva-Burdina M, Rangelov M, Todorova N, Yancheva D. Study on the neuroprotective, radical-scavenging and MAO-B inhibiting properties of new benzimidazole arylhydrazones as potential multi-target drugs for the treatment of Parkinson’s disease. Antioxidants. 2022;11(5):884–1552.
   Web of Science ®Google Scholar
• Ugwu DI, Okoro UC, Ukoha PO, Gupta A, Okafor SN. Novel anti-inflammatory and analgesic agents: synthesis, molecular docking and in vivo studies. J Enzyme Inhib Med Chem. 2018;33(1):405–415.
   PubMed Web of Science ®Google Scholar
• Lad NP, Manohar Y, Mascarenhas M, Pandit YB, Kulkarni MR, Sharma R, Salkar K, Suthar A, Pandit SS. Methylsulfonyl benzothiazoles (MSBT) derivatives: search for new potential antimicrobial and anticancer agents. Bioorg Med Chem Lett. 2017;27(5):1319–1324.
   PubMed Web of Science ®Google Scholar
• Siddiqui N, Alam MS, Sahu M, Naim MJ, Yar MS, Alam O. Design, synthesis, anticonvulsant evaluation and docking study of 2-[(6-substituted benzo[d]thiazol-2-ylcarbamoyl)methyl]-1-(4-substituted phenyl)isothioureas. Bioorg Chem. 2017;71:230–243.
   PubMed Web of Science ®Google Scholar
• Payaz DU, Kucukbay FZ, Kucukbay H, Angeli A, Supuran CT. Synthesis carbonic anhydrase enzyme inhibition and antioxidant activity of novel benzothiazole derivatives incorporating glycine, methionine, alanine, and phenylalanine moieties. J Enzyme Inhib Med Chem. 2019;34(1):343–349.
   PubMed Web of Science ®Google Scholar
• Nam M-H, Park M, Park H, Kim Y, Yoon S, Sawant VS, Choi JW, Park J-H, Park KD, Min S-J, et al. Indole-substituted benzothiazoles and benzoxazoles as selective and reversible MAO-B inhibitors for treatment of Parkinson’s disease. ACS Chem Neurosci. 2017;8(7):1519–1529.
   PubMed Web of Science ®Google Scholar
• Sudevan ST, Rangarajan TM, Al-Sehemi AG, Nair AS, Koyiparambath VP, Mathew B. Revealing the role of the benzyloxy pharmacophore in the design of a new class of monoamine oxidase-B inhibitors. Arch Pharm. 2022;355(8):e2200084.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu J, Yang X, Cai P, Liu Q, Wang KDG, Kong L, Wang X. Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson’s disease. Bioorg Med Chem. 2016;24(22):5929–5940.
   PubMed Web of Science ®Google Scholar
• Hassan RM, Aboutabl ME, Bozzi M, El-Behairy MF, El Kerdawy AM, Sampaolese B, Desiderio C, Vincenzoni F, Sciandra F, Ghannam IAY, et al. Discovery of 4-benzyloxy and 4-(2-phenylethoxy) chalcone fibrate hybrids as novel PPARα agonists with anti-hyperlipidemic and antioxidant activities: design, synthesis and in vitro/in vivo biological evaluation. Bioorg Chem. 2021;115:105170.
   PubMed Web of Science ®Google Scholar
• Yeon SK, Choi JW, Park J-H, Lee YR, Kim HJ, Shin SJ, Jang BK, Kim S, Bahn Y-S, Han G, et al. Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson’s disease therapy. Bioorg Med Chem. 2018;26(1):232–244.
   PubMed Web of Science ®Google Scholar
• Li SY, Wang XB, Kong LY. Design, synthesis and biological evaluation of imine resveratrol derivatives as multi-targeted agents against Alzheimer’s disease. Eur J Med Chem. 2014;71:36–45.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xu H, Zhang W, Wang B, Jiang Y. A novel benzothiazole-based fluorescent probe for cysteine detection and its application on test paper and in living cells. Talanta. 2018;176:151–155.
   PubMed Web of Science ®Google Scholar
• Ma J, Chen D, Lu K, Wang L, Han X, Zhao Y, Gong P. Design, synthesis, and structure-activity relationships of novel benzothiazole derivatives bearing the ortho-hydroxy N-carbamoylhydrazone moiety as potent antitumor agents. Eur J Med Chem. 2014;86:257–269.
   PubMed Web of Science ®Google Scholar
• Weissbach H, Smith TE, Daly JW, Witkop B, Udenfriend S. A rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J Biol Chem. 1960;235(4):1160–1163.
   PubMed Web of Science ®Google Scholar
• Chimenti F, Secci D, Bolasco A, Chimenti P, Bizzarri B, Granese A, Carradori S, Yáñez M, Orallo F, Ortuso F, et al. Synthesis, molecular modeling, and selective inhibitory activity against human monoamine oxidases of 3-carboxamido-7-substituted coumarins. J Med Chem. 2009;52(7):1935–1942.
   PubMed Web of Science ®Google Scholar
• Legoabe LJ, Petzer A, Petzer JP. Selected C7-substituted chromone derivatives as monoamine oxidase inhibitors. Bioorg Chem. 2012;45:1–11.
   PubMed Web of Science ®Google Scholar
• Chavarria D, Fernandes C, Silva V, Silva C, Gil-Martins E, Soares P, Silva T, Silva R, Remião F, Oliveira PJ, et al. Design of novel monoamine oxidase-B inhibitors based on piperine scaffold: structure-activity-toxicity, drug-likeness and efflux transport studies. Eur J Med Chem. 2020;185:111770.
   PubMed Web of Science ®Google Scholar
• Legoabe LJ, Petzer A, Petzer JP. α-Tetralone derivatives as inhibitors of monoamine oxidase. Bioorg Med Chem Lett. 2014;24(12):2758–2763.
   PubMed Web of Science ®Google Scholar
• Harfenist M, Heuser DJ, Joyner CT, Batchelor JF, White HL. Selective inhibitors of monoamine oxidase. 3. structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. J Med Chem. 1996;39(9):1857–1863.
   PubMed Web of Science ®Google Scholar
• Li W, Yang X, Song Q, Cao Z, Shi Y, Deng Y, Zhang L. Pyridoxine-resveratrol hybrids as novel inhibitors of MAO-B with antioxidant and neuroprotective activities for the treatment of Parkinson’s disease. Bioorg Chem. 2020;97:103707.
   PubMed Web of Science ®Google Scholar
• Chavarria D, Da Silva O, Benfeito S, Barreiro S, Garrido J, Cagide F, Soares P, Remião F, Brazzolotto X, Nachon F, et al. Fine-tuning the biological profile of multitarget mitochondriotropic antioxidants for neurodegenerative diseases. Antioxidants. 2021;10(2):329.
   Web of Science ®Google Scholar
• Zhang L, Liu Y, Hu X, Wang Y, Xu M. Metal ion interactions with methyl gallate characterized by UV spectroscopic and computational methods. Food Chem. 2019;293:66–73.
   PubMed Web of Science ®Google Scholar
• Tang Y-W, Shi C-J, Yang H-L, Cai P, Liu Q-H, Yang X-L, Kong L-Y, Wang X-B. Synthesis and evaluation of isoprenylation-resveratrol dimer derivatives against Alzheimer’s disease. Eur J Med Chem. 2019;163:307–319.
   PubMed Web of Science ®Google Scholar
• Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem. 2003;38(3):223–232.
   PubMed Web of Science ®Google Scholar
• Cao Z, Song Q, Yu G, Liu Z, Cong S, Tan Z, Deng Y. Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Bioorg Med Chem. 2021;35:116074.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zheng Y, Luo Y, Du Y, Zhang X, Fu J. Curcumin inhibits LPS-induced neuroinflammation by promoting microglial M2 polarization via TREM2/TLR4/NF-κB pathways in BV2 cells. Mol Immunol. 2019;116:29–37.
   PubMed Web of Science ®Google Scholar
• Tang JJ, Wang MR, Dong S, Huang LF, He QR, Gao JM. 1,10-Seco-eudesmane sesquiterpenoids as a new type of anti-neuroinflammatory agents by suppressing TLR4/NF-κB/MAPK pathways. Eur J Med Chem. 2021;224:113713.
   PubMed Web of Science ®Google Scholar
• Fang Y, Xia W, Cheng B, Hua P, Zhou H, Gu Q, Xu J. Design, synthesis, and biological evaluation of compounds with a new scaffold as anti-neuroinflammatory agents for the treatment of Alzheimer’s disease. Eur J Med Chem. 2018;149:129–138.
   PubMed Web of Science ®Google Scholar
• Ding T, Wang S, Zhang X, Zai W, Fan J, Chen W, Bian Q, Luan J, Shen Y, Zhang Y, et al. Kidney protection effects of dihydroquercetin on diabetic nephropathy through suppressing ROS and NLRP3 inflammasome. Phytomedicine. 2018;41:45–53.
   PubMed Web of Science ®Google Scholar